22
Participants
Start Date
January 27, 2012
Primary Completion Date
November 25, 2015
Study Completion Date
November 25, 2015
Dovitinib
500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Novartis
INDUSTRY
M.D. Anderson Cancer Center
OTHER